Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375575 | 0.89 | KMT2A (0.57) | L3MBTL1RAB9ACA12CA1CA2 | |
| SCHEMBL31078541 | 0.78 | CA12 (0.44) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL28342955 | 0.77 | MEN1 (0.46) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL375504 | 0.76 | KMT2A (0.54) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL5257251 | 0.76 | KDM4A (0.41) | L3MBTL1RAB9ACA12CA1CA2 | |
| SCHEMBL31078784 | 0.75 | L3MBTL1 (0.57) | L3MBTL1RAB9AKMT2APTPRCPTPN1 | |
| SCHEMBL3161402 | 0.75 | CA12 (0.52) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL4831596 | 0.74 | RAB9A (0.55) | L3MBTL1RAB9AKMT2APTPRCPTPN1 | |
| SCHEMBL29713682 | 0.74 | CA12 (0.47) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL2477878 | 0.74 | LMNA (0.39) | L3MBTL1RAB9AIDO1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632460-B1 | THIOPHENE DERIVATIVES FOR USE IN THE TREATMENT OF TUBERCULOSIS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2408770-B1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | Univ Virginia Patent Found (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130317070-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2632460-A2 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | University Of Virginia Patent Foundation (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012040170-A2 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2408770-A2 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | University Of Virginia Patent Foundation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010107736-A2 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317070-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | NRDC, TST, TBCD | L3MBTL1 3129/4885RAB9A 1936/4885CA12 4759/4885 |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | NMT1, MLEC, EPN1 | L3MBTL1 1475/4885RAB9A 3418/4885CA12 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.